Observed Survival Benefit with Limited Exposure of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer at a Large Community-Based Institution

The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.